These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28199803)

  • 1. T-Cell Transfer Therapy Targeting Mutant KRAS.
    Rosenberg SA; Tran E; Robbins PF
    N Engl J Med; 2017 Feb; 376(7):e11. PubMed ID: 28199803
    [No Abstract]   [Full Text] [Related]  

  • 2. T-Cell Transfer Therapy Targeting Mutant KRAS.
    Rech AJ; Vonderheide RH
    N Engl J Med; 2017 Feb; 376(7):e11. PubMed ID: 28207208
    [No Abstract]   [Full Text] [Related]  

  • 3. T-Cell Transfer Therapy Targeting Mutant KRAS.
    Maoz A; Rennert G; Gruber SB
    N Engl J Med; 2017 Feb; 376(7):e11. PubMed ID: 28207209
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutant RAS Calms Stressed-Out Cancer Cells.
    Bryant KL; Der CJ
    Dev Cell; 2017 Jan; 40(2):120-122. PubMed ID: 28118599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies.
    Kaufman J; Stinchcombe TE
    JAMA; 2017 May; 317(18):1835-1837. PubMed ID: 28492885
    [No Abstract]   [Full Text] [Related]  

  • 6. KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.
    Symvoulakis EK; Zaravinos A; Zoras O; Spandidos DA
    Int J Biol Markers; 2011; 26(4):276-7. PubMed ID: 22139644
    [No Abstract]   [Full Text] [Related]  

  • 7. KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers.
    Edgren H; Kangaspeska S; Kallioniemi O
    Cancer Discov; 2011 Jun; 1(1):12-3. PubMed ID: 22586312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A step towards treating KRAS-mutant NSCLC.
    Goldberg SB; Schlessinger J; Boyer JL; Herbst RS
    Lancet Oncol; 2013 Jan; 14(1):3-5. PubMed ID: 23200176
    [No Abstract]   [Full Text] [Related]  

  • 9. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
    Wu C; Wang S; Xu C; Tyler A; Li X; Andersson C; Oji Y; Sugiyama H; Chen Y; Li A
    Cell Physiol Biochem; 2015; 35(2):647-62. PubMed ID: 25613309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
    Keller G; Geist B; Slotta-Huspenina J; Langer R; Nagl F; Fend F; Höfler H; Perren A
    Int J Cancer; 2009 Dec; 125(11):2744-5. PubMed ID: 19521964
    [No Abstract]   [Full Text] [Related]  

  • 11. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.
    Sanclemente M; Nieto P; Garcia-Alonso S; Fernández-García F; Esteban-Burgos L; Guerra C; Drosten M; Caleiras E; Martinez-Torrecuadrada J; Santamaría D; Musteanu M; Barbacid M
    Cancer Cell; 2021 Mar; 39(3):294-296. PubMed ID: 33513349
    [No Abstract]   [Full Text] [Related]  

  • 12. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutations in non-small cell lung cancer.
    Riely GJ; Marks J; Pao W
    Proc Am Thorac Soc; 2009 Apr; 6(2):201-5. PubMed ID: 19349489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.
    Tímár J
    Curr Opin Oncol; 2014 Mar; 26(2):138-44. PubMed ID: 24463346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Climbing RAS, the everest of oncogenes.
    Russo M; Di Nicolantonio F; Bardelli A
    Cancer Discov; 2014 Jan; 4(1):19-21. PubMed ID: 24402942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic activating mutations are associated with local copy gain.
    Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
    Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Kras-specific function in cancer initiation].
    Quinlan MP; Settleman J
    Ai Zheng; 2008 Jul; 27(7):673-4. PubMed ID: 18606056
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation analysis as a diagnostic tool.
    Yan B; Chin SY; Ismail TM; Salto-Tellez M
    Int J Colorectal Dis; 2011 Aug; 26(8):1083-4. PubMed ID: 21128077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.